Mankind Pharma Limited (MANKIND)
Investor Presentation
Investor Presentation - Q2FY27
- Revenue 4,338 Cr +17.3% y-y; EBITDA 1,175 Cr (margin 27.1%, +210 bps y-y); PAT 716 Cr +37.7% y-y
- Domestic business ex-Consumer Healthcare grew 15.9% with 1.1x volume outperformance to IPM
- International business grew 33%; Consumer Healthcare segment showed muted growth
- Recent acquisition of Armed Cell Therapeutics marks entry into next-gen CAR-T therapies
- Strong brand growth in chronic and acute segments; 63 brands with sales above Rs 50 Cr
- Net debt at 2,639 Cr with Net Debt/Adj. EBITDA at 0.6x
- ROCE at 14% on TTM basis excluding BSV acquisition
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 MANKIND — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add MANKIND to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Mankind Pharma Limited
Important.
The summary above is generated automatically from Mankind Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.